Get the Stockscreener App
5.85
4.72%
-0.29
Nuvation Bio Inc stock is traded at $5.85, with a volume of 5.38M.
It is down -4.72% in the last 24 hours and down -32.45% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
See More
Previous Close:
$6.14
Open:
$6.21
24h Volume:
5.38M
Relative Volume:
0.64
Market Cap:
$2.01B
Revenue:
-
Net Income/Loss:
$-75.80M
P/E Ratio:
-16.71
EPS:
-0.35
Net Cash Flow:
$-68.07M
1W Performance:
-27.24%
1M Performance:
-32.45%
6M Performance:
+162.33%
1Y Performance:
+130.31%
1-Day Range:
$5.8202
$6.25
1-Week Range:
$5.8202
$7.6998
52-Week Range:
$1.54
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
(415) 754-3517
Address
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Compare NUVB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
5.85 | 2.10B | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-19-25 | Initiated | B. Riley Securities | Buy |
| Sep-30-25 | Initiated | Jefferies | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
Aug Closing: Whats the analyst consensus on Surrozen IncLong Setup & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Is Nuvation Bio (NUVB) Pricing In Its Sharp Swings Or A Long Runway For Growth - Yahoo Finance
Signal Recap: Should I invest in KORE Group Holdings Inc before earningsJuly 2025 Earnings & Fast Moving Stock Trade Plans - baoquankhu1.vn
A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal - Yahoo Finance
Is Nuvation Bio Inc stock undervalued right nowMarket Growth Report & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Eisai and Nuvation Bio ink licensing deal for taletrectinib - The Pharma Letter
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib - Insider Monkey
Jones Trading raises Nuvation Bio stock price target to $12 on safusidenib study - Investing.com Australia
Q1 EPS Estimates for Nuvation Bio Boosted by HC Wainwright - MarketBeat
Nuvation Bio (NUVB) Expands Global Taletrectinib Rights With Eisai Collaboration And Licensing Deal - simplywall.st
Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens - TechStock²
Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights
Nuvation Bio stock price target lowered to $17 at H.C. Wainwright - Investing.com Nigeria
Weekly Earnings: Will Nuvation Bio Inc stock outperform value stocksJobs Report & Free Safe Capital Growth Stock Tips - moha.gov.vn
Down 24% in 4 Weeks, Here's Why Nuvation Bio (NUVB) Looks Ripe for a Turnaround - Yahoo Finance
Nuvation Bio stock rating reiterated at Market Outperform by Citizens - Investing.com Nigeria
Nuvation Bio and Eisai license Taletrectinib rights outside US, China and Japan for $230 M - BioSpectrum Asia
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan - Quamnet
Nuvation Bio Faces Challenges Amidst Financial and Market Turbulence - StocksToTrade
NUVB Stock Dips Amidst Market Uncertainty and Strategic Pressure - StocksToTrade
Expert Outlook: Nuvation Bio Through The Eyes Of 9 Analysts - Benzinga
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
NUVB Stock Surges Following Promising Expansion News - timothysykes.com
Nuvation Bio (NYSE:NUVB) Shares Gap Down After Analyst Downgrade - MarketBeat
HC Wainwright Has Lowered Expectations for Nuvation Bio (NYSE:NUVB) Stock Price - MarketBeat
Nuvation Stocks Dip on Hookup with Japanese Firm - Baystreet.ca
Nuvation Bio (NUVB): HC Wainwright & Co. Lowers Price Target, Ma - GuruFocus
Nuvation Bio Expands Global Reach with Eisai Partnership - TipRanks
Nuvation Bio Reports Preliminary Fourth Quarter And Full Year 2025 Financial Results And Provides 2026 Outlook Ahead Of 44Th Annual J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Nuvation Bio Signs License and Collaboration Agreement With Eisai - TradingView — Track All Markets
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan - The AI Journal
Nuvation Bio and Eisai enter into exclusive licensing agreement for taletrectinib in Europe and additional countries outside U.S., China and Japan - marketscreener.com
Wall Street Analysts Believe Nuvation Bio (NUVB) Could Rally 25.14%: Here's is How to Trade - MSN
Why Nuvation Bio Inc. Warrants stock gets analyst attentionWeekly Stock Recap & Fast Gain Swing Trade Alerts - Улправда
Hennion & Walsh Asset Management Inc. Has $1.26 Million Stock Holdings in Nuvation Bio Inc. $NUVB - MarketBeat
Moving Averages: How Nuvation Bio Inc stock reacts to bond yieldsVolume Spike & Long-Term Investment Growth Plans - moha.gov.vn
Nuvation Bio stock falls as UBS starts coverage; NUVB investors eye JPM conference next week - TechStock²
A Look At Nuvation Bio (NUVB) Valuation After The Recent UBS Downgrade - Sahm
Nuvation Bio Inc. (NUVB) Stock Analysis: 32.81% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Is Nuvation Bio Inc. stock positioned for long term growth2025 Major Catalysts & Technical Pattern Recognition Alerts - ulpravda.ru
How Nuvation Bio Inc. stock reacts to oil pricesPortfolio Gains Report & Consistent Profit Alerts - ulpravda.ru
How Nuvation Bio Inc. stock reacts to bond yieldsJuly 2025 Momentum & Low Drawdown Investment Ideas - ulpravda.ru
Is Nuvation Bio Inc. stock safe for conservative investorsMarket Risk Report & Daily Momentum Trading Reports - ulpravda.ru
Why Nuvation Bio Inc. Class stock remains stableJuly 2025 Earnings & Safe Investment Capital Preservation Plans - ulpravda.ru
Why Nuvation Bio Inc. stock is trending among retail tradersWeekly Trade Summary & Weekly Chart Analysis and Guides - ulpravda.ru
Aug Swings: Why Nuvation Bio Inc. stock is trending among retail traders2025 Price Targets & Long-Term Growth Portfolio Plans - ulpravda.ru
How Nuvation Bio Inc. stock reacts to global recession fears2025 Short Interest & Step-by-Step Swing Trade Plans - ulpravda.ru
RBC Raises Price Target on Nuvation Bio to $9 From $8, Keeps Outperform, Speculative Risk - MarketScreener
UBS Initiates Coverage of Nuvation Bio (NUVB) with Neutral Recommendation - Nasdaq
Nuvation Bio Inc.'s (NYSE:NUVB) institutional investors lost 5.2% last week but have benefitted from longer-term gains - Yahoo Finance
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):